Appointed
John McAdory
Chief Operating Officer
ONCY ·
ONCOLYTICS BIOTECH INC
appointed John McAdory as Chief Operating Officer of the Company
Ready 8-Ks
16
Latest filing
June 2, 2026, 9:02 AM ET
Top materiality
0.85
Event mix
other_material ×11 · regulatory ×3 · leadership ×2
Sentiment
11 pos · 0 neg · 5 neu
Executive change
recent →
Recent 8-K filings for ONCY
Highest-materiality recent filing
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
- Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
- Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
-
Oncolytics appoints Steve Glover to board, promotes John McAdory to COO
Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.
-
Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.
-
Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.
-
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
-
Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep
FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.
-
Oncolytics Biotech enters ATM agreement for up to $75M common stock offering
Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
-
Oncolytics schedules Type C FDA meeting for pelareorep single-arm study in anal cancer
FDA meeting set for April 16, 2026 to discuss single-arm pivotal study of pelareorep + checkpoint inhibitor in SCAC.
-
Redomestication from Canada to Nevada completed; common stock continues trading on Nasdaq under ONCY.
-
Oncolytics completes continuance to BC; expects Nevada domestication by March 31
First step completed March 17: continuance from Alberta to British Columbia under BCBCA.
-
Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer
GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
-
Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
-
Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed
Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
-
FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.
-
Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards
John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).
-
Oncolytics shareholders OK continuance to BC and domestication to Nevada
Continuance from Alberta to British Columbia approved: 85.21% in favor.
-
GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
Executive changes
Appointed
Stephen Glover
Director
ONCY ·
ONCOLYTICS BIOTECH INC
appointed Stephen Glover as the ninth director of the Board
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material